| Autor: |
Lioznov, M., El-Cheikh, J., Hoffmann, F., Hildebrandt, Y., Ayuk, F., Wolschke, C., Atanackovic, D., Schilling, G., Badbaran, A., Bacher, U., Fehse, B., Zander, A R., Blaise, D., Mohty, M., Kröger, N. |
| Předmět: |
|
| Zdroj: |
Bone Marrow Transplantation; Feb2010, Vol. 45 Issue 2, p349-353, 5p, 2 Charts, 1 Graph |
| Abstrakt: |
We investigated efficacy and toxicity of lenalidomide in 24 heavily pretreated myeloma patients with a median age of 59 years (range: 37–70) and relapse after allo-SCT. Lenalidomide was given at a dose of 15 mg (n=4), or 25 mg (n=20), orally once daily on day 1 to day 1 every 28 days, with (n=20) or without (n=4) DHAP. The median number of lenalidomide cycles was five (range: 2–17). Major side effects were leukopenia (grade 4: 4%, grade 3: 21% and grade 2: 17%) and thrombocytopenia (grade 3: 17% and grade 2: 29%); infectious complications were observed in 50%. Non-hematological toxicity consisted of muscle cramps (n=9), fatigue (n=5) and constipation (n=2). Mild grade I–II GVHD was seen in three patients. Response was achieved in 66%: CR in 8%, VGPR in 8%, PR in 50% and SD in 13%. The median time to progression was 9.7 months (95% confidence interval (CI): 7.5–11.9), and median OS was 19.9 months (95% CI: 17.3–22.5). Immunomonitoring after lenalidomide showed significant increase of activated NK (NKp44+) and T (HLA-DR+) cells, as well as regulatory T cells (CD4+, CD25+, CD127lo), supporting an immunomodulating anti-myeloma effect of lenalidomide. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
